GENX Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: October 21, 2024
Report Source: 2024 2nd Quarter Report
Genex Pharmaceutical Inc. Stock Analysis GENX
United States Health Care Nano Cap Report: Genex Pharmaceutical, Inc. engages in the development and production of Reconstituted Bone Xenograft, which is a medical device that accelerates bone healing. The company is headquartered in Tianjin, Tianjin and currently employs 86 full-time employees. The company went IPO on 2006-05-23. The Company’s main business is engaged in producing and distributing Reconstituted Bone Xenograft (RBX). The RBX is a medical device that accelerates bone healing. The firm distributes its medical devices to hospitals as well as other medical device customers that are not hospitals.
Read More Genex Pharmaceutical Inc (GENX) Chart
Key Statistics of Genex Pharmaceutical Inc (GENX)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$0.00Volume
200.00P/E Ratio (TTM)
0.0152 Week Range
Market Cap
3569.20Avg. Volume
200.00Dividend Yield
-Financial Metrics & Statements of Genex Pharmaceutical Inc (GENX)
FAQ's for Genex Pharmaceutical Inc (GENX)
- According to Musaffa’s Shariah screening methodology, Genex Pharmaceutical Inc (GENX) is currently classified as NOT HALAL as of October 2024. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.